Northern Trust Corp Instil Bio, Inc. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.4 - $0.63 $32 - $50	-80 Reduced 0.08%	106,295 $45,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $0.67 $205,770 - $270,326	-403,472 Reduced 79.14%	106,375 $58,000
Q1 2023 May 15, 2023	SELL	$0.6 - $0.91 $12,666 - $19,210	-21,110 Reduced 3.98%	509,847 $336,000
Q4 2022 Feb 13, 2023	SELL	$0.48 - $5.33 $11,485 - $127,536	-23,928 Reduced 4.31%	530,957 $334,000
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $310,731 - $492,492	66,824 Added 13.69%	554,885 $2.69 Million
Q2 2022 Aug 12, 2022	BUY	$4.21 - $11.15 $377,708 - $1 Million	89,717 Added 22.52%	488,061 $2.26 Million
Q1 2022 May 13, 2022	SELL	$8.48 - $18.1 $121,806 - $259,988	-14,364 Reduced 3.48%	398,344 $4.28 Million
Q4 2021 Feb 08, 2022	BUY	$15.37 - $22.5 $3.9 Million - $5.71 Million	253,621 Added 159.42%	412,708 $7.06 Million
Q3 2021 Nov 15, 2021	SELL	$15.05 - $23.28 $436,028 - $674,468	-28,972 Reduced 15.41%	159,087 $2.84 Million
Q2 2021 Aug 13, 2021	BUY	$15.31 - $24.63 $2.88 Million - $4.63 Million	188,059 New	188,059 $3.63 Million

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $8.8B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.